Document is current
Any future updates will be listed below
-
Authors
Haymond, Morey W https://orcid.org/0000-0003-0631-2913
Araújo-Vilar, David https://orcid.org/0000-0003-2852-7851
Balser, John
Lewis, James H https://orcid.org/0000-0001-5720-3405
Louzado, Ruth
Musso, Carla
von Schnurbein, Julia https://orcid.org/0000-0001-9918-664X
Wabitsch, Martin https://orcid.org/0000-0001-6795-8430
,
-
Funding
Funding for this research was provided by:
Amryt Pharmaceuticals Inc. (N/A)
- License Information
-
More Information
Article History
Received: 23 January 2023
Accepted: 30 April 2023
First Online: 26 May 2023
Declarations
:
: MEASuRE was approved by the ethics committees of each of the participating centers. All patients provided informed consent for participation in MEASuRE.
: All patients provided informed consent for their data to be used in MEASuRE and its subsequent publications.
: MWH chairs an advisory board for Amryt Pharmaceuticals Inc.DA-V has received fees for lectures from Amryt Pharma, for meeting registration, travel and/or accommodation from Aegerion Pharmaceuticals and Amryt Pharma and has received institutional research funding from Aegerion Pharmaceuticals.JB is a contractor for Amryt Pharmaceuticals Inc.JHL has no conflicts to declare.RL is an employee of Amryt Pharmaceuticals DAC.CM has no conflicts to declare.JvS received honoraria for speaking engagements from Amryt Pharmaceuticals in 2018 and 2022.MW has received honoraria for speaking engagements and advisory board participation from Amryt Pharmaceuticals.
